Top 2 4th Quarter Trades of Qiming U.S. Ventures Management, LLC

Qiming U.S. Ventures Management, LLC recently filed their 13F report for the fourth quarter of 2022, which ended on 2022-12-31.

The 13F report details which stocks were in a guru’s equity portfolio at the end of the quarter, though investors should note that these filings are limited in scope, containing only a snapshot of long positions in U.S.-listed stocks and American depository receipts as of the quarter’s end. They are not required to include international holdings, short positions or other types of investments. Still, even this limited filing can provide valuable information.

11100 NE 8th St., Suite 200 Bellevue, WA 98004

As of the latest 13F report, the guru’s equity portfolio contained 7 stocks valued at a total of $76.00Mil. The top holdings were ICVX(36.87%), VTYX(32.37%), and HLVX(12.37%).

According to GuruFocus data, these were Qiming U.S. Ventures Management, LLC’s top five trades of the quarter.

Ventyx Biosciences Inc


Qiming U.S. Ventures Management, LLC reduced their investment in NAS:VTYX by 163,936 shares. The trade had a 2.78% impact on the equity portfolio. During the quarter, the stock traded for an average price of $22.14.

On 01/25/2023, Ventyx Biosciences Inc traded for a price of $36.71 per share and a market cap of $2.08Bil. The stock has returned 144.57% over the past year.

GuruFocus gives the company a financial strength rating of 8 out of 10 and a profitability rating of 1 out of 10.

In terms of valuation, Ventyx Biosciences Inc has a price-book ratio of 5.42 and a EV-to-Ebitda ratio of -17.26.

HilleVax Inc


The guru established a new position worth 558,923 shares in NAS:HLVX, giving the stock a 8.48% weight in the equity portfolio. Shares traded for an average price of $11.87 during the quarter.

On 01/25/2023, HilleVax Inc traded for a price of $15.34 per share and a market cap of $511.52Mil. The stock has returned 0.00% over the past year.

GuruFocus gives the company a financial strength rating of 7 out of 10 and a profitability rating of 2 out of 10.

In terms of valuation, HilleVax Inc has a price-book ratio of 1.69 and a EV-to-Ebitda ratio of -1.37.


Please note, the numbers and facts quoted are as of the writing of this article and may not factor in the latest trading data or company announcements.

When GuruFocus covers insider information, we only track open market or the private purchase and sale of common stock with the transaction code of P or S. Therefore, all the transactions mentioned in this article are only the ones with transaction code of P or S.

Want to provide feedback on this article? Have questions or concerns? Get in touch with us here, or email us at [email protected]!

This article is general in nature and does not represent the opinions of GuruFocus or any of its affiliates. This article is not intended to be financial advice, nor does it constitute investment advice or recommendations. It was written without regard to your individual situation or financial goals. We aim to bring you fundamental, data-driven analysis, The information on this site is in no way guaranteed for completeness, accuracy or in any other way.